Mariner
SGMT icon

Mariner’s Sagimet Biosciences SGMT Stock Holding History

Mariner’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$300K Hold
38,800
– – ﹤0.01% 2848
2026
Q1 		$203K Buy
38,800
+6,700
+21% +$37.3K ﹤0.01% 3156
2025
Q4 		$190K Buy
32,100
+7,000
+28% +$50.3K ﹤0.01% 3187
2025
Q3 		$172K Buy
25,100
+10,200
+68% +$82.7K ﹤0.01% 3226
2025
Q2 		$114K Hold
14,900
– – ﹤0.01% 3218
2025
Q1 		$48.6K Buy
+14,900
New +$62.5K ﹤0.01% 3314

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Mariner's SGMT Position: Q2 2026 in Review

Mariner held its Sagimet Biosciences (SGMT) position steady in Q2 2026 at 38,800 shares worth $300K. The position accounts for ﹤0.01% of the portfolio, ranked #2848.

Mariner first reported a position in SGMT in Q1 2025 and has held it in 6 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Mariner held 38,800 shares of Sagimet Biosciences worth $300K as of Q2 2026.
  • Mariner left its Sagimet Biosciences share count unchanged in Q2 2026.
  • Sagimet Biosciences made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2848 holding.
  • Mariner first reported a position in Sagimet Biosciences in Q1 2025 and has held it in 6 quarters since.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.